Therapeutic Areas · Immunology and Inflammation
Immune-mediated inflammatory diseases span rheumatology, gastroenterology, dermatology and respiratory medicine, and share a common operational challenge: heterogeneous populations, composite endpoints and long treatment periods that make retention as decisive as recruitment.
Overview
Inflammatory disease programs are defined by measurement. Composite indices such as ACR response, DAS28, PASI and clinical and endoscopic remission scores carry substantial subjectivity, so consistency between assessors matters more than in most therapeutic areas. Central reading, rater qualification and ongoing assessor monitoring are what keep the effect size real rather than noise.
Guosa Life Sciences supports immunology and inflammation programs from early proof-of-mechanism through confirmatory and post-approval studies. Our teams coordinate the biomarker and immunogenicity sampling these trials depend on, manage the cold-chain and laboratory workflows that biologics require, and operate across the United States, Sub-Saharan Africa, Asia, Europe and MENA so that recruitment reaches genuinely diverse populations.
Areas of Expertise
Specialized Capabilities
Why GLS
Immunology programs fail on measurement drift more often than on mechanism. We qualify every assessor against the index in use, monitor scoring consistency through the study rather than at the end, and route imaging and endoscopy to central readers so that a site changing personnel in month fourteen does not change the data. Long-term extensions are planned from the outset, because a program that recruits well and retains poorly answers nothing.
The capability
We support immune-mediated inflammatory disease programs across rheumatology, gastroenterology, dermatology and respiratory medicine, from proof of mechanism through confirmatory and post-approval studies, including biosimilar development.
These programs share an operational profile: heterogeneous populations, composite endpoints, long treatment periods and long-term extensions. Retention is as decisive as recruitment, and a program that enrolls well but retains poorly answers nothing, so extension planning belongs in the original design rather than in an amendment.
Regulatory considerations
Immunology endpoints rest on composite indices such as ACR response, DAS28, PASI and clinical and endoscopic remission scores. These carry substantial subjectivity, which means consistency between assessors matters more than in most therapeutic areas. Authorities expect rater qualification against the specific index in use, and expect it to be maintained rather than performed once at initiation.
Central reading is the standard response for imaging and endoscopy endpoints, and it should be specified with the reading charter, reader training and adjudication process in place before first patient. Immunogenicity assessment is a parallel requirement for biologics and biosimilars: anti-drug antibody sampling schedules, assay validation and the interpretation framework need to be agreed at protocol stage, because retrofitting them after enrollment rarely produces an interpretable dataset.
How an engagement runs
Endpoint and index selection, immunogenicity sampling strategy, and extension planning defined before enrollment.
Rater qualification, central reading charter and reader training, laboratory and cold chain setup for biologic handling.
Ongoing scoring consistency monitoring, retention management and central review of imaging and endoscopy.
Analysis with documented handling of intercurrent events, and long-term extension continuity.
What you receive
Rater qualification and ongoing consistency records. A central reading charter with reader training documentation. An immunogenicity sampling and assay plan. Retention reporting against plan.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
Other Therapeutic Areas
Preventive and therapeutic vaccines, pandemic preparedness.
ExploreEarly-phase through global Phase III.
ExploreComplex endpoints and assessment.
ExploreAsthma, COPD and acute infection.
ExploreMaternal and reproductive health.
ExploreCardiovascular, diabetes and metabolic.
ExploreSmall, dispersed populations.
ExploreDevice and diagnostic studies.
ExplorePopulation and vaccination programs.
ExploreDiscuss your dermatology program with our multidisciplinary team.